Simon Turton

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.

Insense Ltd. develops products for treatment of wounds and skin conditions. Its development activity is concentrated on dermatology products for both professional and consumer applications. The company was founded in 2001 by Paul James Davis and is headquartered in Bedford, the United Kingdom.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Diamond Circle Capital Plc is a closed end investment company. Its investment objective of the company is to seek long-term appreciation of its portfolio of Diamonds. It intends to create a portfolio of polished diamonds for long-term investment. The company was founded on May 29, 2007 and is headquartered in Douglas, Isle of Man.

Socure, Inc. provides online identity verification application. It develops ways to mitigate identity fraud risks for businesses. The firm's Social Biometrics technology applies artificial intelligence and machine-learning techniques with online/offline data intelligence from email, phone, address, IP, social media and the broader Internet to authenticate identities in real-time. The company was founded by Johnny Ayers and Sunil Madhu in 2012 and is headquartered in New York, NY.

Diacore International Ltd. manufactures and trades diamond. It specializes in the creation of large, fancy coloured and rare stones. The company is headquartered in Fort Lauderdale, FL.

Scottish Amicable Plc provides financial and commercial services. The private company is based in Craigforth, UK and has subsidiaries in United Kingdom.

Revera Asset Management Ltd. (Revera) is a boutique fund management firm headquartered in Edinburgh, UK. The firm was founded by Glen D. Nimmo in 2003 and they were acquired by AssetCo Plc (LON: ASTO) in 2022. Revera manages UK equity funds for institutional and advisory investors as well as segregated investment mandates for family offices and institutional investors.

Diabetology Ltd. offers biopharmaceutical research and development services. It develops Capsulin and novel Axcess oral form of insulin for diabetics that incorporates absorption enhancers with unmodified bioactive in a convenient encapsulated form. The company was founded by Roger New and Glen Travers in 2002 and is headquartered in St. Helier, Jersey.

Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.

Midatech Pharma (Wales) Ltd. develops advanced life science and therapeutic products. The company was founded on October 10, 2003 and is headquartered in Cardiff, the United Kingdom.

EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France.

Merck Serono Ltd. provides research and development services and manufactures medicinal drugs. The company is headquartered in Middlesex, the United Kingdom.

Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.

Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany.

Midatech Ltd. engages in research and experimental development on biotechnology services. The company is headquartered in Abingdon, the United Kingdom.

Part of Lazard Ltd., Lazard & Co. Holdings Ltd. is a financial advisory and British investment solutions company. The company is based in London, UK. The company's mission is to provide trusted and independent financial advice to its clients, backed by the intellectual capital of the firm. Lazard has been a leading advisor to debtors and creditors in the world's largest and most complex restructurings for decades.

Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland.

ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany.

SpaceCode Holding SA operates as a holding company whose subsidiaries provide asset tracking system solutions and manufactures diamonds and jewellery. It offers implementation services, prospective customers, and technical support. The company was founded by Pavlo Protopapa and Craig Richard Cook in 2005 and is headquartered in Geneva, Switzerland.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

Harefield Pharmacovigilance Ltd. engages in the provision of drug safety services. The company was founded on August 23, 2007 and is headquartered in Guildford, the United Kingdom.

In4derm Ltd. specializes in the discovery of drugs for the treatment of skin diseases. The company is based in Dundee, UK.